Literature DB >> 17637748

Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.

C Berenguer1, F Boudouresque, C Dussert, L Daniel, X Muracciole, M Grino, D Rossi, K Mabrouk, D Figarella-Branger, P-M Martin, L'Houcine Ouafik.   

Abstract

Neuroendocrine (NE) differentiation in prostate cancer (CaP) has been reported to be an early marker associated with the development of androgen independence. The mechanisms by which CaP acquires NE properties are poorly understood. In this study, a putative role of adrenomedullin (AM) in the NE differentiation was investigated. The expression of AM and AM receptors (calcitonin receptor-like receptor (CRLR)/receptor activity modifying protein-2 and -3 (RAMP2 and RAMP3) was evaluated after experimental manipulation of androgen status. Levels of AM mRNA and immunoreactive AM (ir-AM) increased four- to sevenfold in androgen-sensitive LNCaP cells after androgen withdrawal in vitro and in LNCaP xenografts in animals after castration. Treatment of LNCaP cells with androgen analogue (dihydrotestosterone; 10(-9) M) prevented the increase in AM mRNA and ir-AM levels. Interestingly, the expression of CRLR, RAMP2 and RAMP3 is not regulated by androgen status. We demonstrate that in the presence of serum, AM is able to induce an NE phenotype in LNCaP cells via CRLR/RAMP2 and RAMP3, which includes extension of neuritic processes and expression of the neuron-specific enolase (NSE), producing cGMP in a dose-dependent manner, which is mediated by a pertussis toxin-sensitive GTP-binding protein. 8-Bromo-cGMP mimicked the effects of AM on cell differentiation. We demonstrate that AM induces a G-kinase Ialpha translocation to the nucleus. The protein kinase G inhibitor KT-5823 inhibited the neurite outgrowth induced by both AM and 8-bromo-cGMP. In noncastrated animals, administration of AM enhanced expression of NSE and chromogranin A in LNCaP xenografts with a significant increase of NSE levels in serum and no changes in tumor growth. In castrated animals, intraperitoneal injection of AM resulted in a 240+/-18% (P<0.001) increase in tumor volume 36 days after treatment, indicating that the nature of effect of AM in CaP depends on the presence or absence of endogenous androgen. Together, these results demonstrate that AM may function as a mediator of NE-like differentiation in culture as well as in vivo and indicate that its production may be important for tumor resurgence following androgen ablation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17637748     DOI: 10.1038/sj.onc.1210656

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22.

Authors:  Cheryl D Cropp; Claire L Simpson; Tiina Wahlfors; Nati Ha; Asha George; MaryPat S Jones; Ursula Harper; Damaris Ponciano-Jackson; Tiffany A Green; Teuvo L J Tammela; Joan Bailey-Wilson; Johanna Schleutker
Journal:  Int J Cancer       Date:  2011-04-20       Impact factor: 7.396

Review 2.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

Review 3.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

4.  Adrenomedullin promotes intrahepatic cholangiocellular carcinoma metastasis and invasion by inducing epithelial-mesenchymal transition.

Authors:  Chuang Zhou; Yan Zheng; Lin Li; Wenlong Zhai; Renfeng Li; Zhiwen Liang; Longshuan Zhao
Journal:  Oncol Rep       Date:  2015-06-05       Impact factor: 3.906

Review 5.  Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.

Authors:  Chang-Deng Hu; Richard Choo; Jiaoti Huang
Journal:  Front Oncol       Date:  2015-04-14       Impact factor: 6.244

Review 6.  Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.

Authors:  Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  Front Oncol       Date:  2015-02-02       Impact factor: 6.244

Review 7.  Adrenomedullin and tumour microenvironment.

Authors:  Ignacio M Larráyoz; Sonia Martínez-Herrero; Josune García-Sanmartín; Laura Ochoa-Callejero; Alfredo Martínez
Journal:  J Transl Med       Date:  2014-12-05       Impact factor: 5.531

8.  Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion.

Authors:  Zohra Benyahia; Nadège Dussault; Mylène Cayol; Romain Sigaud; Caroline Berenguer-Daizé; Christine Delfino; Asma Tounsi; Stéphane Garcia; Pierre-Marie Martin; Kamel Mabrouk; L'Houcine Ouafik
Journal:  Oncotarget       Date:  2017-02-28

9.  Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo.

Authors:  Emilie Nouguerède; Caroline Berenguer; Stéphane Garcia; Bahia Bennani; Christine Delfino; Isabelle Nanni; Laetitia Dahan; Mohamed Gasmi; Jean-François Seitz; Pierre-Marie Martin; L'houcine Ouafik
Journal:  Cancer Med       Date:  2013-01-29       Impact factor: 4.452

10.  Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.

Authors:  Jingwen Zhao; Yu Zhao; Liguo Wang; Jun Zhang; R Jeffrey Karnes; Manish Kohli; Guixia Wang; Haojie Huang
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.